Market prospects build for continuous glucose monitoring after bullish American Diabetes Association results
This article was originally published in Clinica
Executive Summary
Excitement is building in the US over the prospects for continuous glucose monitoring (CGM) devices, fuelled by several promising studies released at this year's annual meeting of the American Diabetes Association (ADA), in Washington, DC. "Overall, we were generally surprised by the enthusiasm for CGM," said Morgan Stanley analyst Glenn Reicin, who came away from the meeting concluding that the technology "looks to be a potentially significant market".